colorectal%20cancer
COLORECTAL CANCER
Colorectal cancer is a carcinoma arising from the luminal surface of the colon.
It is the 2nd most common cancer in women and third most common cancer in male worldwide. It commonly arises from adenomatous polyps.
It is strongly linked to age with 83% occurring in people ≥60 years old.
Rectal cancer is defined as cancerous lesions located within 12 cm of the anal verge.
Drug Information

Indication: In combination w/ fluoropyrimidine-based chemotherapy for metastatic colon or rectum carcinoma. In combination...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid for advanced colorectal cancer in patients w/o prio...

Indication: Alone or in combination for palliative treatment of malignant tumours, particularly of breast, colon or rectum...

Indication: Advanced colorectal cancer in combination w/ 5-fluorouracil & folinic acid in patients w/o prior chemother...

Indication: Certain megaloblastic anaemia resulting from folic acid deficiency in infant, during pregnancy, in malabsorpti...

Indication: Epidermal growth factor receptor (EGFR) expressing RAS wild-type metastatic colorectal cancer, in combination ...

Indication: In combination w/ docetaxel for locally advanced or metastatic breast cancer after cytotoxic chemotherapy fail...

Indication: In combination w/ 5-fluorouracil (5-FU) & folinic acid (FA) for adjuvant treatment of stage III (Duke's C)...

Indication: Remission of subjective & objective symptoms in head & neck, gastric, colorectal, liver, gallbladder, ...

Indication: Adults w/ wild-type RAS metastatic colorectal cancer (mCRC): 1st-line in combination w/ FOLFOX; 2nd-line in co...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.